BlackRock’s Niagen Bioscience NAGE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $17.1M | Sell |
3,871,619
-204,090
| -5% | -$1.1M | ﹤0.01% | 3179 |
|
|
2025
Q4 | $25.9M | Buy |
4,075,709
+98,706
| +2% | +$687K | ﹤0.01% | 2947 |
|
|
2025
Q3 | $37.1M | Buy |
3,977,003
+120,679
| +3% | +$1.22M | ﹤0.01% | 2695 |
|
|
2025
Q2 | $55.6M | Buy |
3,856,324
+239,253
| +7% | +$2.36M | ﹤0.01% | 2386 |
|
|
2025
Q1 | $25M | Buy |
3,617,071
+5,486
| +0.2% | +$34.5K | ﹤0.01% | 2808 |
|
|
2024
Q4 | $19.2M | Buy |
3,611,585
+216,227
| +6% | +$1.18M | ﹤0.01% | 3078 |
|
|
2024
Q3 | $12.4M | Buy |
3,395,358
+279,180
| +9% | +$879K | ﹤0.01% | 3299 |
|
|
2024
Q2 | $8.51M | Buy |
3,116,178
+2,213,225
| +245% | +$7.41M | ﹤0.01% | 3465 |
|
|
2024
Q1 | $3.14M | Sell |
902,953
-1,739
| -0.2% | -$3.22K | ﹤0.01% | 3846 |
|
|
2023
Q4 | $1.29M | Sell |
904,692
-2,809
| -0.3% | -$3.91K | ﹤0.01% | 4180 |
|
|
2023
Q3 | $1.32M | Sell |
907,501
-6,317
| -0.7% | -$9.87K | ﹤0.01% | 4152 |
|
|
2023
Q2 | $1.43M | Buy |
913,818
+12,622
| +1% | +$18.8K | ﹤0.01% | 4184 |
|
|
2023
Q1 | $1.38M | Sell |
901,196
-82,793
| -8% | -$147K | ﹤0.01% | 4214 |
|
|
2022
Q4 | $1.65M | Buy |
983,989
+943
| +0.1% | +$1.5K | ﹤0.01% | 4212 |
|
|
2022
Q3 | $1.21M | Sell |
983,046
-5,843
| -0.6% | -$9.4K | ﹤0.01% | 4410 |
|
|
2022
Q2 | $1.65M | Sell |
988,889
-2,164,820
| -69% | -$4.23M | ﹤0.01% | 4327 |
|
|
2022
Q1 | $7.76M | Sell |
3,153,709
-41,355
| -1% | -$113K | ﹤0.01% | 3720 |
|
|
2021
Q4 | $11.9M | Buy |
3,195,064
+51,383
| +2% | +$277K | ﹤0.01% | 3569 |
|
|
2021
Q3 | $19.7M | Buy |
3,143,681
+25,074
| +0.8% | +$207K | ﹤0.01% | 3287 |
|
|
2021
Q2 | $30.8M | Sell |
3,118,607
-53,733
| -2% | -$469K | ﹤0.01% | 3039 |
|
|
2021
Q1 | $29.6M | Buy |
3,172,340
+275,467
| +10% | +$2.18M | ﹤0.01% | 2954 |
|
|
2020
Q4 | $13.9M | Buy |
2,896,873
+92,329
| +3% | +$450K | ﹤0.01% | 3200 |
|
|
2020
Q3 | $11.2M | Sell |
2,804,544
-23,044
| -0.8% | -$111K | ﹤0.01% | 3156 |
|
|
2020
Q2 | $13M | Buy |
2,827,588
+359,728
| +15% | +$1.61M | ﹤0.01% | 3037 |
|
|
2020
Q1 | $8.05M | Sell |
2,467,860
-4,236
| -0.2% | -$16.3K | ﹤0.01% | 3108 |
|
|
2019
Q4 | $10.7M | Buy |
2,472,096
+152,170
| +7% | +$541K | ﹤0.01% | 3216 |
|
|
2019
Q3 | $9.13M | Buy |
2,319,926
+81,272
| +4% | +$347K | ﹤0.01% | 3249 |
|
|
2019
Q2 | $10.4M | Buy |
2,238,654
+298,126
| +15% | +$1.27M | ﹤0.01% | 3235 |
|
|
2019
Q1 | $8.13M | Buy |
1,940,528
+26,610
| +1% | +$95.9K | ﹤0.01% | 3212 |
|
|
2018
Q4 | $6.57M | Buy |
1,913,918
+485
| +0% | +$1.69K | ﹤0.01% | 3293 |
|
|
2018
Q3 | $8.21M | Buy |
1,913,433
+28,817
| +2% | +$124K | ﹤0.01% | 3326 |
|
|
2018
Q2 | $6.99M | Buy |
1,884,616
+1,775,638
| +1,629% | +$6.74M | ﹤0.01% | 3402 |
|
|
2018
Q1 | $458K | Sell |
108,978
-2,229
| -2% | -$11.7K | ﹤0.01% | 4063 |
|
|
2017
Q4 | $654K | Buy |
111,207
+9,917
| +10% | +$53.6K | ﹤0.01% | 4001 |
|
|
2017
Q3 | $436K | Buy |
101,290
+4,333
| +4% | +$15.8K | ﹤0.01% | 4082 |
|
|
2017
Q2 | $370K | Sell |
96,957
-1,119,292
| -92% | -$3.55M | ﹤0.01% | 4097 |
|
|
2017
Q1 | $3.27M | Buy |
1,216,249
+1,215,257
| +122,506% | +$3.45M | ﹤0.01% | 3511 |
|
|
2016
Q4 | $3K | Hold |
992
| – | – | ﹤0.01% | 3609 |
|
|
2016
Q3 | $3K | Hold |
992
| – | – | ﹤0.01% | 3580 |
|
|
2016
Q2 | $4K | Buy |
+992
| New | +$4.69K | ﹤0.01% | 3550 |
|
Other funds holding NAGE
SW
VCM
TCM
VPM
BlackRock's NAGE Position: Q1 2026 in Review
BlackRock reduced its Niagen Bioscience (NAGE) stake by 5% in Q1 2026, selling an estimated $1.1M and leaving 3,871,619 shares worth $17.1M. The position accounts for ﹤0.01% of the portfolio, ranked #3179.
BlackRock first reported a position in NAGE in Q2 2016 and has held it in 40 quarters since. The position peaked at $55.6M in Q2 2025. 143 funds tracked by Wall St. Rank hold NAGE as of Q1 2026.
- BlackRock held 3,871,619 shares of Niagen Bioscience worth $17.1M as of Q1 2026.
- BlackRock sold 204,090 Niagen Bioscience shares in Q1 2026, an estimated $1.1M.
- Niagen Bioscience made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #3179 holding.
- BlackRock first reported a position in Niagen Bioscience in Q2 2016 and has held it in 40 quarters since.
- BlackRock's Niagen Bioscience position peaked at $55.6M in Q2 2025.
- 143 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2026.
Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.